{
    "clinical_study": {
        "@rank": "100821", 
        "arm_group": {
            "arm_group_label": "Study Group", 
            "arm_group_type": "Experimental", 
            "description": "Participants at age 9 to 17 months of enrollment will receive 2 doses on Menactra vaccine at 3 to 6 months apart"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the immunogenicity and safety of Menactra\u00ae vaccine\n      given as a two-dose series in infants and toddlers.\n\n      Primary Objectives:\n\n        -  To assess the seroprotection rate (percentage of subjects with a serum bactericidal\n           assay using human complement [SBA-HC] titer \u2265 1:8) 28 days after the second of 2 doses\n           of Menactra\u00ae administered 3 to 6 months apart.\n\n      Secondary Objectives:\n\n        -  To assess the immune responses to meningococcal antigens (serogroups A, C, Y, and\n           W-135) 28 days following the second vaccination with Menactra\u00ae using SBA-HC and SBA-BR\n           titers.\n\n        -  To assess the safety profile of Menactra\u00ae after each and any vaccination."
        }, 
        "brief_title": "Immunogenicity and Safety of Menactra\u00ae Vaccine in Subjects Aged 9 to 23 Months in India and in the Russian Federation", 
        "completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Meningitis", 
            "Meningococcal Infection"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Meningitis", 
                "Meningococcal Infections"
            ]
        }, 
        "detailed_description": {
            "textblock": "Study participants will receive 2 doses on Menactra\u00ae vaccine at 3 to 6 months apart and will\n      be monitored for safety and immunogenicity.\n\n      The planned duration of each subject's participation in the trial will be from 118 to 215\n      days."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male and female subjects aged 9 to 17 months on the day of inclusion\n\n          -  Informed consent form has been signed and dated by the parent(s) or other legally\n             acceptable representative(s) (if applicable)\n\n          -  Subject and parent/legally acceptable representative (if applicable) able to attend\n             all scheduled visits and to comply with all trial procedures. Exclusion Criteria:\n\n          -  Participation in the 4 weeks preceding inclusion or planned participation during the\n             present trial period in another clinical trial investigating a vaccine, drug, medical\n             device, or medical procedure.\n\n          -  Receipt of any vaccine in the 4 weeks preceding each trial vaccination or planned\n             receipt of any vaccine in the 4 weeks following each trial vaccination, except for\n\n          -  influenza vaccination, which may be received at least 2 weeks before study vaccines.\n\n          -  measles (M) or measles, mumps, rubella (MMR) routine vaccination, which can be\n             administered concomitantly with the first dose of study vaccine as per routine\n             immunization schedule\n\n          -  Previous vaccination against meningococcal disease with either the study vaccine or\n             another meningococcal vaccine\n\n          -  Receipt of immune globulins, blood or blood-derived products in the past 3 months\n\n          -  Known or suspected congenital or acquired immunodeficiency; or receipt of\n             immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy,\n             within the preceding 6 months; or long-term systemic corticosteroid therapy\n             (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)\n\n          -  History of meningococcal diseases, confirmed either clinically, serologically, or\n             microbiologically\n\n          -  At high risk, in the opinion of the Investigator, for meningococcal disease during\n             the trial\n\n          -  Known or suspected systemic hypersensitivity to any of the vaccine components, or\n             history of a life-threatening reaction to the vaccine used in the trial or to a\n             vaccine containing any of the same substances\n\n          -  Known thrombocytopenia, contraindicating intramuscular vaccination\n\n          -  Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion,\n             contraindicating intramuscular vaccination\n\n          -  In an emergency setting, or hospitalized involuntarily\n\n          -  Chronic illness that, in the opinion of the investigator, is at a stage where it\n             might interfere with trial conduct or completion\n\n          -  For subjects enrolled at Indian sites: Moderate or severe acute illness/infection\n             (according to investigator judgment) on the day of vaccination or febrile illness\n             (temperature \u2265 38.0\u00b0C).\n\n          -  For subjects enrolled at Russian sites: Acute disease of any severity on the day of\n             vaccination or febrile illness (axillary temperature \u2265 37.0\u00b0C).\n\n        A prospective subject should not be included in the study until the condition has resolved\n        or the febrile event has subsided.\n\n          -  Receipt of oral or injectable antibiotic therapy within 72 hours prior to the first\n             blood draw\n\n          -  Identified as a natural or adopted child of the Investigator or employee with direct\n             involvement in the proposed study\n\n          -  Personal history of Guillain-Barr\u00e9 Syndrome."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "17 Months", 
            "minimum_age": "9 Months"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 27, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01890759", 
            "org_study_id": "MTA70", 
            "secondary_id": "U1111-1122-2171"
        }, 
        "intervention": {
            "arm_group_label": "Study Group", 
            "description": "0.5 mL, Intramuscular", 
            "intervention_name": "Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine", 
            "intervention_type": "Biological", 
            "other_name": "Menactra\u00ae"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Meningitis", 
            "Meningococcal Infection", 
            "Menactra\u00ae"
        ], 
        "lastchanged_date": "January 14, 2014", 
        "link": [
            {
                "url": "http://www.sanofipasteur.com"
            }, 
            {
                "url": "http://www.sanofiaventis.com"
            }
        ], 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Kolkata", 
                        "country": "India", 
                        "state": "West Bengal", 
                        "zip": "700017"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lucknow", 
                        "country": "India", 
                        "zip": "226003"
                    }
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ekaterinburg", 
                        "country": "Russian Federation", 
                        "zip": "620028"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Murmansk", 
                        "country": "Russian Federation", 
                        "zip": "183031"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Perm'", 
                        "country": "Russian Federation", 
                        "zip": "614066"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St Pertersbourg", 
                        "country": "Russian Federation", 
                        "zip": "197022"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "India", 
                "Russian Federation"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "Immunogenicity and Safety of a Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra\u00ae) in Subjects Aged 9 to 23 Months in India and in the Russian Federation", 
        "overall_contact": {
            "email": "RegistryContactUs@sanofipasteur.com", 
            "last_name": "Public Registry Sanofi Pasteur"
        }, 
        "overall_official": {
            "affiliation": "Sanofi Pasteur SA", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "India: Drugs Controller General of India", 
                "Russia: Ministry of Health of the Russian Federation"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "September 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Antibody titers measured by serum bactericidal assay using human complement (SBA-HC). Seroprotection defined as a post-vaccination titer of \u2265 1:8", 
            "measure": "Number of participants with serum bactericidal assay using human complement [SBA-HC] titers \u2265 1:8  post vaccination with Menactra\u00ae", 
            "safety_issue": "No", 
            "time_frame": "Day 28 post second vaccination"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01890759"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Antibody titers measured by serum bactericidal assay using baby rabbit and human complement.", 
                "measure": "Serum Bovine Albumin Baby Rabbit and Human Complement Geometric Mean Titers Following Vaccination With Menactra\u00ae Vaccine", 
                "safety_issue": "No", 
                "time_frame": "Day 28 post second vaccination"
            }, 
            {
                "description": "Antibody titers measured by serum bactericidal assay using baby rabbit  complement (SBA-BR). Seroprotection defined as a post-vaccination titer of \u2265 1:8", 
                "measure": "Number of participants with serum bactericidal assay using baby rabbits complement [SBA-BR] titers \u2265 1:8  post-vaccination with Menactra\u00ae", 
                "safety_issue": "No", 
                "time_frame": "Day 28 post second vaccination"
            }, 
            {
                "description": "Solicited Injection site: Tenderness, Erythema and Swelling: Solicited Systemic: Fever (Temperature), Vomiting, Crying abnormal, Drowsiness, Appetite lost, and Irritability", 
                "measure": "Occurrence and intensity of solicited injection site and systemic reactions and unsolicited adverse events occurring after each Menactra\u00ae vaccination", 
                "safety_issue": "No", 
                "time_frame": "Day 0 up to Month 6 post vaccination"
            }
        ], 
        "source": "Sanofi", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Sanofi Pasteur, a Sanofi Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}